Merck has announced that it has begun construction on a $1 billion, 470,000-square-foot, state-of-the-art biologics center of excellence in Wilmington, Delaware. In addition to enabling the launches and commercial production of next-generation biologics and therapies—including potent antibody-drug conjugates—Merck said it hopes the facility will become the future US home for producing pembrolizumab (under the brand name Keytruda) for US patients. Source: Biopharm International 30/4/2025